Intravenous Iron Better Tolerated Than Oral Iron for Chemotherapy-Induced Anemia

Audiocast Library - Conference Correspondent
Gunnar Birgegård, MD, PhD
Gunnar Birgegård, MD, PhD, discussed his team’s research comparing intravenous iron isomaltoside 1000 with oral iron sulphate monotherapy in patients with cancer and chemotherapy-induced anemia at the 2015 International Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Symposium on Supportive Care in Cancer.
Related Items
Hepatotoxicity a Concern with Frontline Idelalisib
Jennifer Brown, MD, PhD
Audiocast Library published on February 19, 2016 in Conference Correspondent
ASHP Foundation Forecast Provides Actionable Recommendations for Pharmacy Leaders
William A. Zellmer, BPharm, MPH
Audiocast Library published on February 19, 2016 in Conference Correspondent
Formulary Management and Procurement of Oncology Medications
Lindsey B Amerine, PharmD, MS, BCPS
Audiocast Library published on September 10, 2015 in Conference Correspondent
Developing a Pharmacist-Driven Drug-Monitoring Protocol
Felicia Zook, PharmD, BCOP
Audiocast Library published on August 7, 2015 in Conference Correspondent
Meeting USP Chapter 800 Head On
Michael Koraleski, PharmD
Audiocast Library published on August 7, 2015 in Conference Correspondent
Last modified: September 10, 2015